Public Health
Regulatory frameworks, surveillance, and interventions aimed at protecting and improving the health of populations, covering disease outbreak response, vaccination programmes, and health promotion.
Foresight tracks Public Health developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
Intensifying
189% above the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
13 May 2026, 09:20
Latest Public Health alerts
The most recent regulatory and guidance signals tracked by Foresight
US FDA Alerts on New Blood Cancer Risk with Tazverik; Sponsor to Voluntarily Withdraw Product from US Market
US FDA has announced that Ipsen will voluntarily withdraw Tazverik (tazemetostat) tablets from the US market after a new phase 1b/3 trial showed a markedly increased incidence of serious hematologic second primary malignancies in treated patients. This removes Tazverik as a treatment option in the United States and underscores heightened regulatory scrutiny of accelerated-approval oncology drugs, requiring rapid protocol, inventory, and patient-management adjustments by oncology providers and supply-chain partners.
United StatesEU Parliament and Council Reach Provisional Deal on Critical Medicines Act
EU legislators have reached a provisional political deal on the Critical Medicines Act, creating an EU framework to fund strategic manufacturing projects and reshape procurement rules to strengthen supply of critical medicines. This will tilt public funding and tenders towards resilient EU-based suppliers and joint procurement mechanisms, signalling future obligations for manufacturers and buyers to prioritise secure European supply once the regulation is formally adopted.
European UnionCalifornia Updates WIC Food Benefits and Authorized Food List
California public health authorities have implemented USDA’s 2024 WIC food package revisions by updating the state’s WIC food benefits and authorised food list, expanding eligible whole grains, dairy alternatives, canned fish and fresh herbs for participants from May 2026. For retailers authorised to accept WIC in California, this locks in a refreshed 2026 authorised product set and POS rules, requiring inventories, coding and customer guidance to stay aligned with the new CDPH WIC food list and shopping guide.
United StatesEU Commission Amends Marketing Authorisation for Docetaxel Accord (Docetaxel)
The European Commission has issued Implementing Decision C(2026)3288 to amend the existing marketing authorisation for the cancer medicine Docetaxel Accord (docetaxel), originally granted by Decision C(2012)3454. Regulatory teams should obtain the full decision text, confirm what conditions or product information have changed, and implement any required updates to EU labelling, SmPC and quality systems to maintain marketing-authorisation compliance.
European UnionNetherlands Government Outlines Industrial Emissions and PFAS Measures in Action Agenda "Industry and Neighbours"
The Dutch government has answered parliamentary questions on the Industry and Neighbours Action Agenda, clarifying how it will implement the revised EU Industrial Emissions and Air Quality directives and manage PFAS, steel slag and other industrial pollution through pilots, permit reforms and research running into 2026–2027. This signals that operators of large Dutch industrial installations should prepare for stricter default BAT-based permitting, closer health-driven scrutiny and potential partial PFAS discharge bans, even though most measures will first be tested via pilots before translating into binding national rules.
NetherlandsEMA CMDh Adopts PSUSA Variation for Choline Salicylate and Cetalkonium Chloride
CMDh has finalised PSUSA/00000626/202508 for choline salicylate and cetalkonium chloride, requiring updated pregnancy, gastrointestinal and concomitant salicylate warnings in the product information for all nationally authorised medicines in the EU and setting a 9 July 2026 deadline for submission of variation applications. Marketing authorisation holders must identify affected licences, update SmPCs and package leaflets, and coordinate national variation filings to meet the EU timetable and avoid non-compliance with pharmacovigilance obligations.
European UnionUS FDA Requests Information on Drug Repurposing for Unmet Medical Needs
In May 2026, the US Food and Drug Administration opened a 30-day public consultation seeking input on priority disease areas and FDA-approved drugs that could be repurposed to address unmet medical needs where no sponsor is currently pursuing a new indication. This initiative could shape future regulatory pathways, labeling updates, and market opportunities for off-patent drugs, so API and finished-drug manufacturers should assess whether their portfolios include candidates and consider contributing data or comments before the June 11 deadline.
United StatesUS FDA Classifies Orthopedic Infection Nucleic Acid and Resistance Marker Device as Class II With Special Controls
FDA has finalized a class II (special controls) classification and codified a new device type at 21 CFR 866.3988 for nucleic-acid-based diagnostics that detect microorganisms and resistance markers in suspected orthopedic infections in the United States. This creates a defined 510(k) pathway and clear validation, labeling, and sample-collection expectations that manufacturers of such multiplex orthopedic infection panels must meet when bringing products to or updating them on the US market.
United StatesCalifornia AB 2442 — Peptides Working Group Bill Referred to Appropriations Suspense File
California lawmakers are advancing AB 2442, a bill to convene a state public health working group on investigational peptide and novel therapeutic compounds, with the measure now before the Assembly Appropriations Committee and its first hearing set for 14 May 2026. If enacted, this time-limited framework could shape how manufacturers, clinics, and researchers develop, test, and provide investigational peptide-based therapies in California, signalling potential future state expectations for oversight and access.
United StatesEstonia: April 2026 Safety Changes to Medicinal Product Information for Eight Medicines
In May 2026 the Estonian Medicines Agency published updated safety information for eight medicines, adding new warnings, adverse reactions and interaction advice to April 2026 product information for products marketed in Estonia. Marketing authorisation holders should confirm Estonian summaries of product characteristics and patient leaflets for these substances reflect the revised safety information and adjust pharmacovigilance and risk communication practices accordingly.
EstoniaSwitzerland Amends Reporting Office Ordinance to Require Weekly Stock and Shortage Reporting for Vital Human Medicines
In May 2026, the Swiss Federal Council amended the ordinance on the reporting office for vital human medicines to introduce weekly stock level reporting and stricter shortage notifications for marketing-authorisation holders, effective 15 June 2026. This will force manufacturers and MA holders of critical medicines in Switzerland to enhance inventory monitoring and data connections to the Therapeutic Products Platform so they can report stock levels and emerging shortages quickly enough to avoid supply risks and regulatory intervention.
SwitzerlandEU Commission Plans 2026 Revision of Tobacco Products and Advertising Directives
In May 2026 the European Commission told Parliament it has completed its evaluation of the EU tobacco control directives and plans to propose a revision of the framework in 2026. This signals that significant changes to EU requirements for tobacco and nicotine products could arrive from 2026 onwards, so manufacturers and retailers should track upcoming impact assessments and consultations and prepare for potential shifts in product, packaging, and marketing rules.
European UnionNetherlands Plans 1 August 2026 Entry Into Force of ‘Wet Veilige Jaarwisseling’ Fireworks Ban
The Dutch government is moving to set 1 August 2026 as the entry into force date for the Wet veilige jaarwisseling and its implementing decree, enabling a nationwide ban on consumer fireworks from the 2026–2027 New Year period, subject to completion of a heavy parliamentary pre-notification procedure. This effectively locks in the transition timeline for municipalities and the fireworks sector, which must prepare for a near-total consumer fireworks ban with only limited mayoral exemptions and an accompanying compensation scheme once the decree is formally adopted.
NetherlandsCommission Implementing Decision (EU) 2026/1023 Establishing an EU Staff Exchange Programme on Official Controls of Animals and Goods Entering the Union
In May 2026 the European Commission adopted Implementing Decision (EU) 2026/1023, creating a three-year EU staff exchange programme for Member State authorities responsible for official controls on animals and goods entering the Union. While it introduces no direct new obligations for operators, the programme is designed to harmonise and strengthen risk-based border controls under the Official Controls Regulation, signalling a gradual tightening and convergence of enforcement on agri-food and related imports.
European UnionNetherlands Sets Target 1 August 2026 for Consumer Fireworks Ban and Retailer Compensation Scheme
In May 2026 the Dutch government answered parliamentary questions on fireworks retailers, confirming the principles of a targeted compensation scheme and its aim to bring the Safe New Year’s Eve Act and Decree, which introduce a nationwide consumer fireworks ban, into force on 1 August 2026 subject to final parliamentary approval. For fireworks importers and retailers this points to a likely hard stop for most consumer fireworks sales from that date, with compensation limited to losses beyond normal business risk and only narrow exemptions for organised displays, making early transition, inventory management, and business model planning critical.
NetherlandsUS FDA Finalizes Guidance for Developing Drugs to Treat Pulmonary Tuberculosis
In May 2026 FDA issued final, non-binding guidance for industry on designing clinical development programs for drugs to treat pulmonary tuberculosis, updating a 2022 draft after public comment. This clarifies expectations on trial design, study populations, endpoints, and nonclinical safety, giving TB drug developers a clearer roadmap for evidence packages likely to meet U.S. approval standards.
United StatesSwitzerland OSAV Issues Public Warning And Recall For MaiThai Herbal Tablets With Undeclared Pharmacologically Active Substances
In May 2026, Switzerland's food safety authority OSAV warned consumers after MaiThai herbal tablets containing undeclared dexamethasone, paracetamol and chlorphenamine were withdrawn from sale and recalled. The case highlights enforcement risk from adulterated "herbal" products and underscores the need for tighter supplier vetting, ingredient controls, and recall readiness for companies selling supplements and similar tablets in Switzerland.
SwitzerlandManitoba Fire Bulletin #1 Details 2026 Wildfire Preparedness and Burn Restrictions
Manitoba has issued Fire Bulletin #1 and a 2025 Wildfire Interim After Action Review setting out investments, staffing increases, and operational changes to strengthen provincial readiness for the 2026 wildfire season. For operators and communities in Manitoba this means tighter enforcement of existing open-fire restrictions, more coordinated evacuation and emergency management capacity, and a clearer framework for planning around increasingly severe wildfire seasons.
CanadaSwiss Federal Council Adopts Early-Warning Reporting Rules For Essential Human Medicines
In May 2026 Switzerland adopted amendments to its ordinance on the reporting office for vital human medicines, transforming the WL digital monitoring platform into a proactive early-warning system that takes effect on 15 June 2026. Marketing authorisation holders of essential medicines must now provide detailed weekly stock data and rapid shortage notifications via an automated interface, significantly tightening visibility over supply risks and reducing duplicated reporting across the federal administration.
SwitzerlandBrazil – Deputy To Propose Subcommittee On Beer Advertising Restrictions Under Law 9.294/1996
Brazil’s Chamber of Deputies used a 5 May 2026 hearing to call for updating Law 9.294/1996 so that beer – which makes up most alcohol consumption – would fall under existing restrictions on advertising for alcoholic beverages, and Deputy Erika Kokay announced she will propose a subcommittee to work on this. If this initiative and the related PL 1548/2025 bill advance, beverage producers and advertisers could face significantly tighter controls and warning requirements for beer marketing, especially online, so this is an early signal for compliance and campaign planning teams to monitor.
BrazilNot a newsletter. Not a feed.
Structured intelligence mapped to your business.
These are just a few of the most recent Public Health alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialFrequently asked questions
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Join 3,500+ professionals staying ahead
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
